These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11576359)

  • 21. [Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity].
    González E; Rada MA; Lumbreras C; Ramos JT; Aguado JM
    Enferm Infecc Microbiol Clin; 2000 Apr; 18(4):162-4. PubMed ID: 10932392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
    Dutta A; Palazzi DL
    Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
    Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
    Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
    Barcia JP
    Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amphotericin B revisited: reassessment of toxicity.
    Clements JS; Peacock JE
    Am J Med; 1990 May; 88(5N):22N-27N. PubMed ID: 2368770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
    Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
    Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
    Paterson DL; David K; Mrsic M; Cetkovsky P; Weng XH; Sterba J; Krivan G; Boskovic D; Lu M; Zhu LP;
    J Antimicrob Chemother; 2008 Dec; 62(6):1392-400. PubMed ID: 18812423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amphotericin B-induced nephrotoxicity: a review.
    Fanos V; Cataldi L
    J Chemother; 2000 Dec; 12(6):463-70. PubMed ID: 11154026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.
    Craddock C; Anson J; Chu P; Dodgson A; Duncan N; Gomez C; Mehta J; Sadullah S; Subudhi C; Yin JL
    Expert Opin Drug Saf; 2010 Jan; 9(1):139-47. PubMed ID: 19947901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
    Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
    Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
    Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
    Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
    Noskin G; Pietrelli L; Gurwith M; Bowden R
    Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?
    Karimzadeh I; Farsaei S; Khalili H; Dashti-Khavidaki S
    Expert Opin Drug Saf; 2012 Nov; 11(6):969-83. PubMed ID: 22950480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
    van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
    N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
    Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.